Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma  Oliver Noga, MD, Gerald Hanf, MD,

Published byRalf Franke Modified over 5 years ago

Similar presentations

Presentation on theme: "Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma  Oliver Noga, MD, Gerald Hanf, MD,"— Presentation transcript:

1 Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma  Oliver Noga, MD, Gerald Hanf, MD, Ilka Brachmann, MD, Andrea C. Klucken, MD, Jörg Kleine-Tebbe, MD, Simone Rosseau, MD, Gert Kunkel, MD, Norbert Suttorp, MD, Joachim Seybold, MD  Journal of Allergy and Clinical Immunology  Volume 117, Issue 6, Pages (June 2006) DOI: /j.jaci Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

2 Fig 1 Eosinophil apoptosis. Individual values at baseline and week 12 of omalizumab therapy. The omalizumab group (n = 9) demonstrated a significant decrease in Annexin-positive eosinophils compared with placebo (n = 10). In the omalizumab-treated group, a significant decrease of Annexin-positive eosinophils comparing baseline with 12 weeks of treatment was found. Horizontal bars represent medians. ∗∗P < .01. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

3 Fig 2 Intracellular GM-CSF in T lymphocytes. Individual values at baseline and week 12 of omalizumab therapy in (A) GM-CSF+/CD3+ lymphocytes, (B) GM-CSF+CD3/CD4+ lymphocytes, and (C) GM-CSF+CD3/CD8+ lymphocytes. Horizontal bars represent medians. ∗∗P < .01; ∗P < .05. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

4 Fig 3 Intracellular IL-2 in T lymphocytes. Individual values at baseline and week 12 of omalizumab therapy in (A) IL-2+CD3+ lymphocytes, (B) IL-2+CD3/CD4+ lymphocytes, and (C) IL-2+CD3/CD8+ lymphocytes. Horizontal bars represent medians. ∗∗P < .01; ∗P < .05. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

5 Fig 4 Intracellular IL-13 in T lymphocytes. Individual values at baseline and week 12 of omalizumab in (A) IL-13+CD3+ lymphocytes, (B) IL-13+CD3/CD4+ lymphocytes, and (C) IL-13+CD3/CD8+ lymphocytes. Horizontal bars represent medians. ∗∗P < .01; ∗P < .05. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Download ppt "Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma  Oliver Noga, MD, Gerald Hanf, MD,"

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Serum granzymes and CD30 are increased in children's milk protein sensitive enteropathy and celiac disease  Merja T. Augustin, MD, Jorma Kokkonen, MD,

Serum granzymes and CD30 are increased in children's milk protein sensitive enteropathy and celiac disease  Merja T. Augustin, MD, Jorma Kokkonen, MD,
What drives prescription patterns in pediatric asthma management?

What drives prescription patterns in pediatric asthma management?
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,
Serum granzymes and CD30 are increased in children's milk protein sensitive enteropathy and celiac disease  Merja T. Augustin, MD, Jorma Kokkonen, MD,

Serum granzymes and CD30 are increased in children's milk protein sensitive enteropathy and celiac disease  Merja T. Augustin, MD, Jorma Kokkonen, MD,
Pharmacologic rationale for treating allergic and nonallergic rhinitis

Pharmacologic rationale for treating allergic and nonallergic rhinitis
Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy  Akihiko.

Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy  Akihiko.
Alalia Berry, MD, William W. Busse, MD 

Alalia Berry, MD, William W. Busse, MD 
Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Ann-Marie M. Schoos, MD, PhD, Jacob D

Ann-Marie M. Schoos, MD, PhD, Jacob D
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Disparities in allergic disease: Hypersensitivity and social disorders

Disparities in allergic disease: Hypersensitivity and social disorders
Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema  Dagmar Simon, MD, Jennifer Wittwer, MD, Ganna Kostylina,

Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema  Dagmar Simon, MD, Jennifer Wittwer, MD, Ganna Kostylina,
Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,
Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL- 5 and IL-5 receptor levels  Miguel L. Stein, MD, Joyce M. Villanueva,

Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL- 5 and IL-5 receptor levels  Miguel L. Stein, MD, Joyce M. Villanueva,
Long-term immune reconstitution after matched unrelated hematopoietic stem cell transplantation for immunodeficiency  Vy Hong-Diep Kim, MD, Brenda Reid,

Long-term immune reconstitution after matched unrelated hematopoietic stem cell transplantation for immunodeficiency  Vy Hong-Diep Kim, MD, Brenda Reid,
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?

Similar presentations

Ads by Google